Repligen Sets October 5 Vote on $1.5B BioLife Acquisition
RGEN sits 72% above its 52-week low of $100.99.
Summary
Repligen's amended S-4 sets the BioLife stockholder vote for October 5, 2026, on the $1.5 billion acquisition, with the HSR waiting period expiring September 3 and 7.28 million Repligen shares now registered for the deal.
Key Events · M&A and Partnerships · RGEN
-
BioLife Stockholder Vote Set for October 5
The BioLife Special Meeting will be held virtually on October 5, 2026, to vote on the merger proposal, with a record date of September 3, 2026 and 48,923,333 BioLife shares outstanding.
-
HSR Waiting Period Expires September 3
The HSR antitrust waiting period is scheduled to expire at 11:59 p.m. Eastern Time on September 3, 2026, clearing a key regulatory hurdle for the $1.5 billion acquisition.
-
Registration Increased to 7.28M Repligen Shares
Amendment No. 1 registers an additional 74,623 shares of Repligen common stock, bringing the total to 7,277,203 shares issuable in the merger, with an additional filing fee of $8,251.
-
Merger Consideration Unchanged
BioLife stockholders will receive $11.25 in cash plus 0.1442 Repligen shares per BioLife share, implying approximately $36.19 per share based on Repligen's September 2 closing price of $172.94.
Analysis · RGEN · Life Sciences
Amendment No. 1 to the S-4 registration statement advances the $1.5 billion BioLife Solutions acquisition toward completion. The filing sets the BioLife stockholder vote for October 5, 2026, establishes a record date of September 3, 2026 with 48.9 million shares outstanding, and confirms the HSR antitrust waiting period expires September 3, 2026. The registration now covers 7,277,203 shares of Repligen common stock, up 74,623 shares from the initial filing. BioLife stockholders will receive $11.25 in cash plus 0.1442 Repligen shares per BioLife share, implying approximately $36.19 per share based on Repligen's September 2 closing price of $172.94. The deal remains subject to BioLife stockholder approval and regulatory clearances, with closing expected in Q4 2026.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGEN was trading at $173.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6B. The 52-week trading range was $100.99 to $188.73. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.